[Clinical evaluation of cefixime in children].

Abstract

A new beta-lactamase-stable oral cephem antibiotic, cefixime (CFIX), was evaluated for safety, efficacy and pharmacokinetics in children. CFIX was effective in 19 of 20 cases (95%) with bacterial infections. The drug was especially effective against the cases of pneumonia due to beta-lactamase-producing H. influenzae or B. catarrhalis. Pharmacokinetic parameters of CFIX (3 mg/kg) with premeal administration were as follows: Kel 0.328 +/- 0.066 hr-1, T 1/2 2.14 +/- 0.36 hrs, AUC 10.9 +/- 8.7 micrograms X hr/ml, and Vd/F 1.64 +/- 1.42 L/kg. In most of the cases tested, the urinary excretion rate in 12 hours was 5 to 17%. A dose of 3 mg/kg twice daily seems to be adequate for a regular treatment.

• Authors: H Meguro, O Arimasu, H Sohda, J Yoshida, K Togasaki, R Fujii
• Journal: The Japanese journal of antibiotics (Jpn J Antibiot) Vol. 39 Issue 4 Pg. 1007-19 (Apr 1986) ISSN: 0368-2781 [Print] Japan
• PMID: 3761534 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Cefixime
• Cefotaxime

Topics

• Bacterial Infections (drug therapy)
• Cefixime
• Cefotaxime (analogs & derivatives, metabolism, pharmacology, therapeutic use)
• Child
• Child, Preschool
• Female
• Haemophilus Infections (drug therapy)
• Humans
• Infant
• Kinetics
• Male
• Pneumonia (drug therapy)
• Pneumonia, Mycoplasma (drug therapy)
• Respiratory Tract Infections (drug therapy)
• Urinary Tract Infections (drug therapy)